Global, regional, and national burdens of intracerebral hemorrhage and its risk factors from 1990 to 2021
European Journal of Neurology · 2025-01 · 32 (1)
DOI: 10.1111/ene.70031 ↗At a glance
Journal article in European Journal of Neurology, published online on 2024-12-27. Written by Dengpan Song and 10 co-authors. Institution: Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Major MEDLINE topics: Cerebral Hemorrhage, Global Burden of Disease. Cited 22 times so far (Crossref); 23 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (original language)
Background and Purpose The aim of this study was to assess the intracerebral hemorrhage (ICH) burden in 204 countries and territories worldwide from 1990 to 2021, disaggregated by sex, age, and sociodemographic index (SDI) at the global, regional, and country levels.
Methods
Data from the 2021 Global Burden of Disease Study (GBD) were used to calculate age‐standardized prevalence (ASPR), incidence (ASIR), death (ASDR), and disability‐adjusted life year (DALY) rates for ICH. The estimated annual percentage change (EAPC) was used to assess time patterns. The Bayesian age–period–cohort (BAPC) model was employed to predict future ICH burden.
Results
In 2021, the global ICH burden remained high, with a total of 16.6 million cases and an ASPR of 194.51 cases per 100,000 people. The ASIR was 40.83 cases per 100,000 people, the ASDR was 39.09 cases per 100,000 people, and the age‐standardized DALY rate was 923.64 per 100,000 people. The low‐SDI regions had the highest ASPR, ASIR, ASDR, and DALY rates. Geographically, western sub‐Saharan Africa had the highest ASPR, Central Asia had the highest ASIR, and Oceania had the highest ASDR and DALY rates. High systolic blood pressure was the leading risk factor for ICH death, contributing to 57.9% of global fatalities.
Conclusion
Despite the decline in the ASIR, there is an ongoing increase in the absolute number of ICH cases, with significant differences observed across age, sex, region, country, and SDI. More attention and emphasis should be placed on improving the ICH burden in low‐SDI areas.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Department of Neurosurgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Neurosurgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China.
- Department of Anesthesiology, Ochsner LSU Health, Shreveport, Louisiana, USA.
- Department of Neurosurgery, Johns Hopkins University, Baltimore, Maryland, USA.
- Department of Molecular and Translational Medicine (MTM), Texas Tech University Health Science Center El Paso (TTUHSCEP), El Paso, Texas, USA.
ORCID profiles: Dingkang Xu, Fuyou Guo
Funding
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Cite
APA
Song, D., Xu, D., Li, M., Wang, F., Feng, M., Badr, A., Rigamonti, D., Cistola, D., Yan, D., Zhang, J., & Guo, F. (2025). Global, regional, and national burdens of intracerebral hemorrhage and its risk factors from 1990 to 2021. European Journal of Neurology, 32(1). https://doi.org/10.1111/ene.70031
Vancouver
Song D, Xu D, Li M, Wang F, Feng M, Badr A, et al. Global, regional, and national burdens of intracerebral hemorrhage and its risk factors from 1990 to 2021. European Journal of Neurology. 2025;32(1). doi:10.1111/ene.70031
BibTeX
@article{Song2025,
author = {Song, Dengpan and Xu, Dingkang and Li, Mengyuan and Wang, Fang and Feng, Mengzhao and Badr, Ahmed and Rigamonti, Daniele and Cistola, David and Yan, Dongming and Zhang, Jun and Guo, Fuyou},
title = {Global, regional, and national burdens of intracerebral hemorrhage and its risk factors from 1990 to 2021},
journal = {European Journal of Neurology},
year = {2025},
volume = {32},
number = {1},
doi = {10.1111/ene.70031}
}
EUVIMED